SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Ceregene, Inc. today announced that Jeffrey M. Ostrove, Ph.D., president and chief executive officer, will present at the JPMorgan 26th Annual Healthcare Conference in San Francisco, CA on Thursday, January 10th at 11:30 a.m. PST. "We look forward to participating in this pre-eminent healthcare conference and providing a Ceregene update to the investment community," stated Dr. Ostrove. "2007 was a positive year for us during which time we raised our Series C financing, signed a corporate partnership deal with Genzyme and announced encouraging data from both our clinical-stage Parkinson's disease and Alzheimer's disease programs. We expect to report Phase 2 data from our controlled CERE-120 Parkinson's disease study late this year, which could lead to a Phase 3 clinical study in 2009. We also look forward to the initiation of a larger, controlled Phase 2 trial of CERE-110 in Alzheimer's disease later this year." About Ceregene Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth factors for the treatment of neurodegenerative disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in Phase 1/2 studies for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) which recently completed enrollment of a controlled Phase 2 study for Parkinson's disease. CERE-130 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001 and is a former subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE). The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys as well as Hamilton BioVentures and California Technology Partners.
SOURCE Ceregene, Inc.